Ignite Creation Date:
2024-05-06 @ 1:44 AM
Last Modification Date:
2024-10-26 @ 11:08 AM
Study NCT ID:
NCT01880866
Status:
WITHDRAWN
Last Update Posted:
2014-09-10
First Post:
2013-05-28
Brief Title:
--Epicatechin and Pulmonary Arterial Hypertension
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Study Overview
Official Title:
An Open Label Pilot Study of Purified --Epicatechin to Improve Hemodynamics in Pulmonary Arterial Hypertension
Status:
WITHDRAWN
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pulmonary arterial hypertension PAH is a progressive disease that results in severe activity limitation and death There are few treatments for PAH and the available medications are expensive difficult to administer and have significant toxicities
--Epicatechin is a non-toxic compound that naturally occurs in foods such as tea wine and chocolate Clinical intervention studies using dark chocolate in normal volunteers and subjects at risk for or with established cardiovascular disease have demonstrated improvements in peripheral and coronary vascular endothelial function blood pressure lipids glucose tolerance and inflammatory markers
Our study intends to examine the hemodynamics effects of purified --epicatechin in subjects with pulmonary arterial hypertension We hypothesize purified --epicatechin will reduce pulmonary vascular resistance in patients with pulmonary arterial hypertension
--Epicatechin is a non-toxic compound that naturally occurs in foods such as tea wine and chocolate Clinical intervention studies using dark chocolate in normal volunteers and subjects at risk for or with established cardiovascular disease have demonstrated improvements in peripheral and coronary vascular endothelial function blood pressure lipids glucose tolerance and inflammatory markers
Our study intends to examine the hemodynamics effects of purified --epicatechin in subjects with pulmonary arterial hypertension We hypothesize purified --epicatechin will reduce pulmonary vascular resistance in patients with pulmonary arterial hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None